Theratechnologies Confirms Issuance Of U.S. Patent Covering The Use Of Tesamorelin In The Treatment Of Individuals Suffering From NAFLD/NASH
Theratechnologies Confirms Issuance Of U.S. Patent Covering The Use Of Tesamorelin In The Treatment Of Individuals Suffering From NAFLD/NASH
Oct 13, 2020
Montreal, Canada – October 13, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,799,562, which is directed to the treatment of Nonalcoholic Steatohepatitis (NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD) in patients using tesamorelin.